Bernard Lim Acquires 10,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock

Cardiol Therapeutics Inc. (TSE:CRDLGet Free Report) Senior Officer Bernard Lim purchased 10,000 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was bought at an average cost of C$1.95 per share, with a total value of C$19,500.00.

Cardiol Therapeutics Stock Performance

TSE:CRDL opened at C$1.96 on Thursday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 6.84 and a current ratio of 2.39. Cardiol Therapeutics Inc. has a fifty-two week low of C$1.07 and a fifty-two week high of C$4.26. The company has a 50 day simple moving average of C$2.40 and a two-hundred day simple moving average of C$2.71. The company has a market capitalization of C$136.96 million, a PE ratio of -4.45 and a beta of 0.70.

Cardiol Therapeutics Company Profile

(Get Free Report)

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Featured Stories

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.